Cover Image
市場調查報告書

全球幹細胞技術、適應市場:2017年∼2027年

Global Stem Cell Technologies and Applications Market 2017-2027: Cancer, Cardiovascular, CNS, Other Disease Areas and Non-Therapeutic Applications

出版商 Visiongain Ltd 商品編碼 203833
出版日期 內容資訊 英文 261 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球幹細胞技術、適應市場:2017年∼2027年 Global Stem Cell Technologies and Applications Market 2017-2027: Cancer, Cardiovascular, CNS, Other Disease Areas and Non-Therapeutic Applications
出版日期: 2017年03月06日 內容資訊: 英文 261 Pages
簡介

全球幹細胞技術、適應市場,預計2016年∼2027年以11.7%的年複合成長率成長。

本報告提供全球幹細胞技術、適應市場相關調查分析,市場預測,次市場預測,主要產品的收益預測,有前途的開發平台分析,法規環境與發展,市場的推動因素與阻礙因素,影響要素等相關的系統性資訊。

第1章 報告概要

第2章 所謂幹細胞技術、適應

  • 所謂幹細胞,特徵定義
  • 幹細胞研究的時間軸
  • ES細胞 (ESC)的登場
  • 幹細胞的分類:各功能
  • 幹細胞的主要類型和其特性
  • iPS細胞:ES細胞的優點,缺點
  • 單為發生幹細胞:科學性背景
  • 自體 vs. 同種異體幹細胞
  • 臨床實驗的階段
  • 報告的範圍

第3章 國際開發與幹細胞的法規環境

  • 美國的法規環境
  • 歐洲的法規環境
  • 日本的法規環境
  • 韓國的法規環境
  • 中國的法規環境

第4章 幹細胞技術、適應:全球市場

  • 幹細胞的治療適應 vs. 非治療適應
  • 全球市場的各地區
  • 市場區隔
  • 幹細胞技術、適應市場:預測
  • 幹細胞技術、適應市場:預測 (各市場區隔)
  • 各市場區隔的市場佔有率的變化
  • 幹細胞技術、適應市場:推動因素、阻礙因素

第5章 幹細胞癌症治療市場區隔

  • 幹細胞癌症治療:概要與現狀
  • 幹細胞癌症治療:市場預測
  • 造血幹細胞移植 (HSCT)
  • 從治療到產品:臍帶血幹細胞的認證
  • 幹細胞癌症治療開發平台
  • 幹細胞癌症治療:推動因素、阻礙因素

第6章 幹細胞心血管治療市場區隔

  • 幹細胞心血管治療:概要與現狀
  • 幹細胞心血管治療:市場預測
  • 心血管疾病佔全球醫藥品市場大部分
  • 心血管疾病的幹細胞研究狀況
  • 心臟的幹細胞神秘的效果
  • 市售的幹細胞心臟疾病治療
  • 幹細胞心臟疾病治療開發平台
  • 幹細胞心臟疾病治療:推動因素、阻礙因素

第7章 幹細胞中樞神經系統 (CNS) 治療市場區隔

  • 幹細胞CNS治療:概要與現狀
  • 幹細胞CNS治療:市場預測
  • CNS疾病的幹細胞研究狀況
  • 特定的CNS疾病的進步
  • 規模的市場數十億美元
  • 幹細胞CNS治療開發平台
  • 幹細胞CNS治療:推動因素、阻礙因素

第8章 其他疾病的幹細胞治療市場區隔

  • 其他疾病的幹細胞治療:概要與現狀
  • 其他疾病的幹細胞治療:市場預測
  • 其他疾病的幹細胞治療:上市藥
  • 其他疾病的幹細胞治療:研究領域
  • 其他疾病的幹細胞治療:開發平台
  • 基因改造幹細胞治療

第9章 幹細胞非治療適應

  • 幹細胞非治療適應:概要與現狀
  • 幹細胞非治療適應:市場預測
  • 幹細胞銀行:全球需求增加
  • 幹細胞供給、加工:iPS細胞
  • 幹細胞為基礎的化驗:大幅可能性
  • 研究、試劑、其他
  • 推動因素、阻礙因素

第10章 幹細胞技術、適應市場定性分析

  • SWOT分析
  • 優勢
  • 弱點
  • 機會
  • 威脅
  • STEP分析
  • 社會要素
  • 技術性要素
  • 經濟要素
  • 政治要素

第11章 結論

詞彙表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0173

The global stem cell technologies and applications market is expected to grow at a CAGR of 13.4% in the first half of the forecast period and CAGR of 10.5% in the second half of the forecast period. The market is expected to grow at a CAGR of 11.7% from 2016 to 2027. The market is estimated at $10,751 million in 2016 and $17,768 million in 2020.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 257-page report you will receive 114 charts - all unavailable elsewhere.

The 257-page report provides clear detailed insight into the global stem cell technologies and applications market.

Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Stem Cell Technologies and Applications Market forecasts from 2017-2027
  • Global Stem Cell Technologies and Applications submarket forecasts from 2017-2027:
    • Cancer treatment
    • Cardiovascular therapy
    • CNS
    • Other therapies
    • Non-therapeutic applications
  • Individual revenue forecast to 2027 for selected top products:
    • MSC-100-IV (Mesoblast)
    • Hearticellgram-AMI (Pharmicell)
    • CardioRel (Reliance Life Sciences)
    • Osteocel Plus (NuVasive)
    • Trinity Evolution and Elite (Orthofix)
    • CARTISTEM (MEDIPOST)
  • Analysis of the most promising pipeline therapies in each therapeutic segment
  • Discussion on regulatory environments and developments in the US, Japan, Europe and other leading countries
  • Analysis of what drives and restrains the market
  • This study also discusses other influences on that field, including these:
    • Haematopoietic stem cell transplantation (HSCT)
    • Embryonic stem cells (ESCs), induced pluripotent adult (IPSCs) and parthenogenetic cells
    • Uses for umbilical cord blood and related technologies, including cellular and blood banking
    • Agents for osteogenesis and treating autoimmune conditions
    • Applications in cell-based assays, diagnostics and drug development.

Visiongain's study is intended for anyone requiring commercial analyses for the Global Stem Cell Technologies and Applications Market. You find data, trends and predictions.

Buy our report today Global Stem Cell Technologies and Applications Market 2017-2027: Cancer, Cardiovascular, CNS, Other Disease Areas and Non-Therapeutic Applications.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Stem Cell Technologies and Applications Market Overview
  • 1.2. Global Stem Cell Technologies and Applications Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How this Report Delivers
  • 1.5. Key Questions Answered by This Report
  • 1.6. Who is Report for?
  • 1.7. Research and Analysis Methods
  • 1.8. Frequently Asked Questions(FAQ)
  • 1.9. Some Associated Reports
  • 1.10. About Visiongain

2. Introduction to Stem Cell Technologies and Applications

  • 2.1. What are Stem Cells? Defining Characteristics
  • 2.2. Timeline of Stem Cell Research
  • 2.3. Embryonic Stem Cells(ESCs) Enter the Picture
  • 2.4. Classifying Stem Cells by Potency
  • 2.5. The Main Types of Stem Cells and Their Properties
  • 2.6. iPSCs: The Benefits of ESCs, but Without the Downsides?
  • 2.7. Parthenogenetic Stem Cells: Scientific Background
  • 2.8. Autologous Versus Allogeneic Stem Cells
  • 2.9. Phases of Clinical Trials
  • 2.10. Scope of this Report

3. International Developments and Stem Cell Regulatory Environments

  • 3.1. Regulatory Environment in the US
    • 3.1.1. Dynamic Biotechnology Sector and Liberal Stance on Patents
    • 3.1.2. Understanding ‘Homologous' Use
    • 3.1.3. Controversy Surrounding ESC Research
    • 3.1.4. NIH ESC Stem Cell Registry: Has Made Good Progress, but Not Enough for its Critics
    • 3.1.5. CIRM and NIH Stem Cell Funding into Various Channels
    • 3.1.6. FDA vs Regenerative Sciences
    • 3.1.7. Are Stem Cells Clinics the ‘Wild West' of Medicine?
    • 3.1.8. Stem Cell Clinics Using Loopholes to Avoid Oversight?
    • 3.1.9. FDA Releases Three New Draft Guidances, but is it Doing Enough?
  • 3.2. Regulatory Environment in Europe
    • 3.2.1. Unified Overarching System of Regulation Across EU
    • 3.2.2. Difference Between EU Member States Regarding hESC Research
    • 3.2.3. European Court of Justice Performs an U-Turn and Clears Path Towards Stem Cell Patents
    • 3.2.4. The UK: A Leader in European Stem Cell Research
  • 3.3. Regulatory Environment in Japan
    • 3.3.1. Liberal Stance on hESC but with Excessive Bureaucracy?
    • 3.3.2. Japan: A Pioneer in iPSC Research, Although First In-Human Trial has been Suspended
    • 3.3.3. The STAP Cell Events: Excitement Dashed
    • 3.3.4. Government Committed to Regenerative Medicines and iPSC Research
    • 3.3.5. Japan Becomes Very Attractive Market for Stem Cell Companies due to Favourable Regulatory Changes
  • 3.4. Regulatory Environment in South Korea
    • 3.4.1. Highs and Lows with Regard to hESC Research
    • 3.4.2. Regulators are Quick to Approve Therapies, Although this has Drawn Criticism
    • 3.4.3. Tracheal Transplant Patient Dies
  • 3.5. Chinese Regulatory Environment
    • 3.5.1. Liberal Regulation on Stem Cells and Very High Number of Stem Cell Clinical Trials Taking Place in the Country
    • 3.5.2. Stem Cell Medical Tourism Very Popular
    • 3.5.3. CFDA Releases New Stem Cell Draft Guidance

4. Stem Cell Technologies and Applications: World Market 2017-2027

  • 4.1. Therapeutic Applications Versus Non-Therapeutic Applications of Stem Cells
  • 4.2. Regional Breakdown of the World Market
  • 4.3. Market Segmentation
  • 4.4. Stem Cell Technologies and Applications Market: Forecast 2016-2027
  • 4.5. Stem Cell Technologies and Applications Market: Forecast by Segment 2016-2027
  • 4.6. How Will Segmental Market Shares Change to 2027?
    • 4.6.1. Which Segments will grow the Most?
  • 4.7. Stem Cell Technologies and Applications Market: Drivers and Restraints 2016-2027

5. Stem Cell Cancer Therapeutics Segment 2017-2027

  • 5.1. Stem Cell Cancer Therapeutics: Overview and Current Status
  • 5.2. Stem Cell Cancer Therapeutics: Market Forecast 2016-2027
  • 5.3. Haematopoietic Stem Cell Transplantation(HCST)
    • 5.3.1. An Established Treatment for Haematological Cancers
    • 5.3.2. Autologous HSCT: Dominant Form of HSCT
    • 5.3.3. Autologous Versus Allogeneic HSCT: Advantages and Disadvantages
    • 5.3.4. GvHD: The Major Issue for HSCT
    • 5.3.5. Strengths and Weaknesses of the Three Major Sources of HSCs
    • 5.3.6. What is Cord Blood?
    • 5.3.7. Number of HSCT Operations Performed Worldwide, Split by Autologous Versus Allogeneic HSCT, 2012-2014
    • 5.3.8. HSCT Costs and Medicare Coverage
    • 5.3.9. The Indications which can be treated with HSCT: Haematological Malignancies are the Major Indications
    • 5.3.10. HSCT has the Potential to Address Multiple Cancers, which represent a $20bn+ Market
  • 5.4. From Procedures to Products: Cord Blood Stem Cell Approvals
    • 5.4.1. Hemacord(New York Blood Center): The First FDA-Approved Cord Blood Product
    • 5.4.2. HPC, Cord Blood(ClinImmune Labs / University of Colorado Blood Bank)
    • 5.4.3. Ducord(Duke University School of Medicine)
    • 5.4.4. Allocord(SSM Cardinal Glennon Children's Medical Center)
    • 5.4.5. HPC, Cord Blood BLA 125432(LifeSouth Community Blood Centers)
    • 5.4.6. CLEVECORD, HPC
    • 5.4.7. HPC, Cord Blood(BLA 125585)
  • 5.5. Stem Cell Cancer Therapeutics Pipeline
    • 5.5.1. Agenmestencel-T(Apceth)
    • 5.5.2. CLT-008 and CLT-009(Cellerant Therapeutics): Company Receives $47.5m Grant from US Government
    • 5.5.3. ProHema(Fate Therapeutics)
    • 5.5.4. StemEx and NiCord(Gamida Cell)
    • 5.5.5. MSC-100-IV(Previously Known as Prochymal) and Unnamed MPC-Expanded Cord Blood Product(Mesoblast)
    • 5.5.6. HSC835(Novartis)
    • 5.5.7. Ancillary Products for the HSCT Setting
    • 5.5.8. Targeting of Cancer Stem Cells(CSCs)
  • 5.6. Stem Cell Cancer Therapeutics: Drivers and Restraints 2016-2027

6. Stem Cell Cardiovascular Therapeutics Segment 2017-2027

  • 6.1. Stem Cell Cardiovascular Therapeutics: Overview and Current Status
  • 6.2. Stem Cell Cardiovascular Therapeutics: Market Forecast 2016-2027
  • 6.3. Cardiovascular Diseases Make up a Large part of the Global Pharmaceutical Market
    • 6.3.1. Stem Cell Treatments for Stroke: Touched Upon in This Chapter but mainly Covered under Central Nervous System Therapeutics
    • 6.3.2. Cardiovascular and Cerebrovascular Conditions are the World's Most Fatal Diseases
    • 6.3.3. AMI, CLI and Stroke: Major Ischemic Disease Targets
  • 6.4. The State of Stem Cell Research for Cardiovascular Diseases
    • 6.4.1. Practical Advantages to Choosing the Heart as a Target for Stem Cell R&D
    • 6.4.2. Defining Cardiovascular Stem Cells: Scientific Context
  • 6.5. The Mysterious Effects of Stem Cells in the Heart
    • 6.5.1. MSCs in the Heart: Evidence to Support their Use, as well as Doubts over their Efficacy
    • 6.5.2. Cardiosphere-Derived Cells, hESC-Derived Cardiomyocytes and C-kit Cells
  • 6.6. Stem Cell Cardiovascular Therapeutics on the Market
    • 6.6.1. Hearticellgram-AMI(Pharmicell)
    • 6.6.2. CardioRel(Reliance Life Sciences)
  • 6.7. Stem Cell Cardiovascular Therapeutics Pipeline
    • 6.7.1. Ixmyelocel-T(Vericel Corporation)
    • 6.7.2. Alecmestencel-T(Apceth)
    • 6.7.3. Arteriocyte: Using its ‘Magellan System' to Treat CLI
    • 6.7.4. MultiStem(Athersys) for Myocardial Infarction and Stroke
    • 6.7.5. Baxter: Phase 3 CD34+ Stem Cell Therapy for Refractory Angina
    • 6.7.6. CardiAMP(BioCardia) for Heart Failure: Scheduled to Finally Begin Phase 3 in January 2017
    • 6.7.7. MyoCell(U.S. Stem Cell, Inc. - Formerly Bioheart): Autologous ‘Muscle Stem Cell' Therapy
    • 6.7.8. CAP-1001 and CAP-1002(Carpricor): Cardiospehere-Derived Cells for Heart Repair
    • 6.7.9. Ceylad(Formerly Cardio3): Proprietary Cardiopoiesis Technology Platform - Can be Applied to Various Stem Cell Sources
    • 6.7.10. Mesoblast: Mesenchymal Precursor Cells for Heart Failure and Myocardial Infarction
    • 6.7.11. Caladrius Biosciences: Will not Continue Development of CLBS10, the Company's Former Lead Candidate
    • 6.7.12. Stemedica Cell Technologies: ‘Ischaemic-Tolerant' Stem Cell Platform
    • 6.7.13. Gemacell and Cryocell(Human Stem Cells Institute): Awaiting Important Russian Legislation to be Passed before Development Can Continue
  • 6.8. Stem Cell Cardiovascular Therapeutics: Drivers and Restraints 2016-2027

7. Stem Cell Central Nervous System Therapeutics Segment 2017-2027

  • 7.1. Stem Cell Central Nervous System Therapeutics: Overview and Current Status
  • 7.2. Stem Cell Central Nervous System Therapeutics: Market Forecast 2016-2027
  • 7.3. The State of Stem Cell Research in CNS Diseases
    • 7.3.1. Stem Cells are the Best Hope for Many Serious CNS Conditions
    • 7.3.2. Awaiting a First Breakthrough Approval
    • 7.3.3. Human Neural Stem Cells(NSCs) Successfully Isolated
    • 7.3.4. NSCs Reach the Clinic Without Serious Controversy
    • 7.3.5. CNS Disorders are a Major Focus for ESC Research
    • 7.3.6. MSCs: Can Glial Cell and Astrocyte Formation Help Neurological Conditions?
  • 7.4. Progress in Specific CNS Conditions
    • 7.4.1. HSCT in MS: Could ‘Resetting' the Immune System Treat MS?
    • 7.4.2. ALS: Could this Rare Disease be the First Neurodegenerative Condition for Stem Cell Treatment?
    • 7.4.3. Parkinson's Disease: Field Recovering after Voluntary Moratorium on Stem Cell Research by Many Western Nations Ends
    • 7.4.4. Dry Age-Related Macular Degeneration: A Major Unmet Need
  • 7.5. Several Multi-Billion Dollar Markets are Open to Stem Cell Developers if they can Translate the Potential of Stem Cells into Therapies
  • 7.6. Stem Cell Central Nervous System Therapeutics Pipeline
    • 7.6.1. MA09-hRPE(Ocata Therapeutics): Stem Cells for Eye Diseases
    • 7.6.2. NurOwn(BrainStorm Cell Therapeutics): Neurotrophic Factor -Releasing Stem Cells for ALS
    • 7.6.3. International Stem Cell Corporation: Company Signals Intent to Start Phase ½a Study in PD Soon
    • 7.6.4. Neuralstem: Allogeneic NSCs for Synaptic Repair and Neuroprotection
    • 7.6.5. PF-05206388(Pfizer and the London Project to Cure Blindness): Finally Begins Phase 1Trial, with first Successful Surgery
    • 7.6.6. Q-Cells(Q Therapeutics): Phase ½ Trial Begins
    • 7.6.7. ReNeuron: CTX Neural Cell Line and its Advantages
    • 7.6.8. SB623(SanBio): Enters Phase 2 for Stroke, as well as for Traumatic Brain Injury
    • 7.6.9. StemCells, Inc: A Leader in Neural Stem Cells
  • 7.7. Stem Cell Central Nervous System Therapeutics: Drivers and Restraints 2016-2027

8. Stem Cell Therapeutics in Other Disease Areas 2017-2027

  • 8.1. Stem Cell Therapeutics in Other Disease Areas: Overview and Current Status
  • 8.2. Stem Cell Therapeutics in Other Disease Areas: Market Forecast 2016-2027
  • 8.3. Stem Cell Therapeutics in Other Disease Areas: Therapies on the Market
    • 8.3.1. Osteocel Plus(NuVasive)
    • 8.3.2. Trinity Evolution and Trinity Elite(Orthofix): Stem Cell Orthobiologics
    • 8.3.3. CARTISTEM(MEDIPOST)
    • 8.3.4. Allostem(Allosource)
    • 8.3.5. Map3(RTI Surgical)
    • 8.3.6. ReliNethra for Ocular Surface Damage(Reliance Life Sciences)
    • 8.3.7. Cupistem(Anterogen)
  • 8.4. Stem Cell Therapeutics for Other Diseases: Research Areas
    • 8.4.1. HSCT for Orphan Diseases
    • 8.4.2. Potential for Genetically Modified Stem Cells for HIV and Other Diseases?
    • 8.4.3. Stem Cells Contribute to the Osteogenesis Process in Bone Repair
    • 8.4.4. Stem Cells Gaining Increasing Importance in Bone Graft Market, but whether these are True ‘Stem Cell Products' is Debatable
    • 8.4.5. Stem Cells also have Potential in Autoimmune Disorders
    • 8.4.6. Potential Cure for Diabetes?
    • 8.4.7. Stem Cells in Active Liver Repair
    • 8.4.8. Long-Term Possibilities
  • 8.5. Stem Cell Therapeutics in Other Disease Areas: Pipeline
    • 8.5.1. ALLO-ASC and ALLO-ASC-DFU(Anterogen)
    • 8.5.2. MultiStem(Athersys): Fails Phase 2 Ulcerative Colitis, Still Undergoing Phase 1 as Immunomodulation Therapy after Liver Transplantation
    • 8.5.3. BioTime: Multiple Subsidiaries Focused on Regenerative Medicine
    • 8.5.4. Calimmune: Dual Anti-HIV Gene Therapy via Stem Cells
    • 8.5.5(PDA-001 and PDA-002) Celgene Corporation
    • 8.5.6. ReJoin(Cellular Biomedicine Group): Interim Results from the MSCs for Knee Osteoarthritis
    • 8.5.7. PNEUMOSTEM(MEDIPOST)
    • 8.5.8. Translational Biosciences: Set Up for the Sole Purpose of Conduction Stem Cell Clinical Trials, Five Phase ½ Trials Ongoing
    • 8.5.9. Mesoblast: MPCs for Various Indications
    • 8.5.10. Pluristem Therapeutics: Uses PLX Cells to Secrete Therapeutic Proteins in Damaged Tissues
    • 8.5.11. Regeneus: Adipose Derived MSC Therapies
    • 8.5.12. S-Evans Biosciences: Menstrual Stem Cells
    • 8.5.13. TiGenix: Expanded Adipose-Derived Stem Cell Therapies
    • 8.5.14. VC-01(ViaCyte)
  • 8.6. Genetically Modified Stem Cell Therapies
    • 8.6.1. BluebirdBio: Gene-Modified HSCs for Orphan Diseases
    • 8.6.2. GSK: Stem Cell Gene Therapies for Rare Diseases, Including one which has been Submitted for Approval in Europe

9. Stem Cell Non-Therapeutic Applications 2017-2027

  • 9.1. Stem Cell Non-Therapeutic Applications: Overview and Current Status
  • 9.2. Stem Cell Non-Therapeutic Applications: Market Forecast 2016-2027
  • 9.3. Stem Cell Banking: Growing Demand Worldwide
    • 9.3.1. Impact of the current epidemic of Zika Virus and HIV in cord cell banking
    • 9.3.2. Is there a Need for Stem Cell Banking as a Form of ‘Health Insurance'?
    • 9.3.3. Stem Cell Banking Companies in the US and Around the World
    • 9.3.4. Dental Stem Cell Banking: An Alternative to Cord Blood Banks?
  • 9.4. Stem Cell Supply and Processing: iPSCs are the New Driver
    • 9.4.1. Stem Cell Supply and Processing Companies
  • 9.5. Stem Cell-Based Assays: Major Potential for Preclinical Screens
    • 9.5.1. Advantages of Stem Cell-Based Assays
    • 9.5.2. Stem Cell-Based Assay Companies
  • 9.6. Research, Reagents, and Other Non-Therapeutic Stem Cell Activities
  • 9.7. Drivers and Restraints

10. Qualitative Analysis of the Stem Cell Technologies and Applications Market 2017-2027

  • 10.1. SWOT Analysis of the Stem Cell Technologies and Applications Market
  • 10.2. Strengths
    • 10.2.1. HSCT is already an Established Procedure
    • 10.2.2. Approvals for Stem Cell Therapies
    • 10.2.3. Relaxation of Regulatory Barriers
  • 10.3. Weaknesses
    • 10.3.1. Uncertain Mechanisms of Action in Stem Cell Therapies
    • 10.3.2. Phase 3 Trials only make up a Small Fraction of the Currently Ongoing Clinical Trials
    • 10.3.3. Regulatory and Reimbursement Concerns
    • 10.3.4. The scare of a possible immune rejection after a stem cell transplant
  • 10.4. Opportunities
    • 10.4.1. Huge Potential in Unmet Clinical Needs
    • 10.4.2. Opportunities in the Non-Therapeutic Uses of Stem Cells, including Cord Blood Banking and Cell-Based Assays
    • 10.4.3. Interactions with Related Technologies will Offer new Opportunities
    • 10.4.4. Genetic Modification of Stem Cells
  • 10.5. Threats
    • 10.5.1. Financial Risks and Under-Capitalisation of the Stem Cells Sector
    • 10.5.2. Threat of Pipeline Failures
    • 10.5.3. Long-Term Safety Concerns
  • 10.6. STEP Analysis of the Stem Cell Technologies and Applications Market
  • 10.7. Social Factors
    • 10.7.1. Increasing Burden of Disease as World Population Ages
    • 10.7.2. Biological Insurance through Stem Cell Banking
    • 10.7.3. Stem Cell Tourism: Both an Opportunity and Threat to the Market
  • 10.8. fTechnological Factors
    • 10.8.1. Increasing Research Output
    • 10.8.2. IPSC Advances
    • 10.8.3. Greater Understanding of Stem Cell Differentiation
    • 10.8.4. Interactions with Other Technologies
    • 10.8.5. CRISPR: A Breakthrough in Genome Editing
  • 10.9. Economic Factors
    • 10.9.1. Grey Market for Stem Cell Therapies
    • 10.9.2. Broad Changes in Pharma / Healthcare Markets
    • 10.9.3. New Business Models are required due to the Unique Challenges Posed by these Non-Traditional Therapies
  • 10.10. Political Factors
    • 10.10.1. Controversies over Embryonic Stem Cell Research
    • 10.10.2. Support from National Governments
    • 10.10.3. Patient Pressure to Deregulate the Stem Cell Therapies Market

11. Conclusions

  • 11.1. Stem Cell Technologies and Applications: An Emerging Market
  • 11.2. Current Leading Segments and Regional Markets
  • 11.3. World Stem cell Technologies and Applications Market Forecast 2016-2027
  • 11.4. The Future of the Stem Cell Market
  • 11.5. Concluding Remarks

Glossary

  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation form

List of Tables

  • Table 2.1: Classifying Stem Cells by Potency
  • Table 2.2: The Different Germ Layers and Their Associated Types of Cells and Organs
  • Table 2.3: Main Types of Stem Cells and Their Properties
  • Table 2.4: Stem Cell Donor Terminology
  • Table 2.5: The Different Phases of Clinical Trials
  • Table 3.1: NIH Embryonic Stem Cell Registry: Stem Cell Lines by Status, 2015 and 2016
  • Table 3.2: New FDA Draft Guidances, 2016
  • Table 3.3: StemGen's Classifications of European Nations by Level of Permissiveness towards hESC research
  • Table 4.1: Stem Cell Technologies and Applications Market by Region: Revenues ($m), Market Shares (%), 2016
  • Table 4.2: Stem Cell Technologies and Applications Market by Segment: Revenues ($m), Market Shares (%), 2016
  • Table 4.3: Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2020
  • Table 4.4: Stem Cell Technologies and Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2027
  • Table 4.5: Stem Cell Technologies and Applications Market Forecast by Segment: Revenues ($m), AGR (%), CAGR (%), 2016-2020
  • Table 4.6: Stem Cell Technologies and Applications Market Forecast by Segment: Revenues ($m), AGR (%), CAGR (%), 2021-2027
  • Table 4.7: Stem Cell Technologies and Applications Market by Segment: Revenues ($m), Market Share (%), 2021 and 2027
  • Table 5.1: Stem Cell Cancer Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2020
  • Table 5.2: Stem Cell Cancer Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2027
  • Table 5.3: Comparison of Bone Marrow, Peripheral Blood and Cord Blood for HSCT
  • Table 5.4: Estimated Number of HSCT Operations Performed Globally, by Donor Type: AGR (%), CAGR (%), 2012-2014
  • Table 5.5: European HSCT Operations: Number of Operations by Donor Type, 2003-2012
  • Table 5.6: Indications with Medicare Coverage for HSCT (both Autologous and Allogeneic)
  • Table 5.7: Malignancies and Other Haematological Diseases which may be Treated with HSCT
  • Table 5.8: HSCT-Addressable Cancers: Estimated Combined Incidence in the US, Japan and Western Europe (Number of Cases), CAGR (%), 2012-2024
  • Table 5.9: FDA-Approved Cord Blood-Derived Stem Cell Products for HSCT, 2016
  • Table 5.10: Past and Present ProHema (Fate Therapeutics) Clinical Trials, 2016
  • Table 5.11: MSC-100-IV / Temcell HS Forecast (Mesoblast / JCR Pharmaceuticals): Revenues ($m), AGR (%), CAGR (%), 2014-2020
  • Table 5.12: MSC-100-IV / Temcell HS Forecast (Mesoblast / JCR Pharmaceuticals): Revenues ($m), AGR (%), CAGR (%), 2021-2027
  • Table 5.13: HSC835 (Novartis) Ongoing Clinical Trials, 2016
  • Table 6.1: Stem Cell Cardiovascular Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2020
  • Table 6.2: Stem Cell Cardiovascular Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2027
  • Table 6.3: Global Cardiovascular Disease Market by Drug Class: Revenue ($bn), 2016
  • Table 6.4: Projected Global Deaths from Ischaemic Heart Disease and Stroke (millions), % of Total Deaths, Deaths Per 100,000 Population, 2015 and 2030
  • Table 6.5: Advantages, disadvantages and different clinical trials that are ongoing
  • Table 6.6: Hearticellgram-AMI (Pharmicell) Sales Estimates: Revenue ($m), AGR (%), 2014-2016
  • Table 6.7: Hearticellgram-AMI Forecast (Pharmicell): Revenues ($m), AGR (%), CAGR (%), 2014-2020
  • Table 6.8: Hearticellgram-AMI Forecast (Pharmicell): Revenues ($m), AGR (%), CAGR (%), 2021-2027
  • Table 6.9: CardioRel (Reliance Life Sciences) Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2020
  • Table 6.10: CardioRel (Reliance Life Sciences) Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2027
  • Table 6.11: Past and Present MultiStem (Athersys) Clinical Trials, 2016
  • Table 6.12: Ongoing Stemedica Cell Technologies Clinical Trials in Cardiovascular Indications, 2016
  • Table 7.1: Stem Cell CNS Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2020
  • Table 7.2: Stem Cell CNS Therapeutics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2027
  • Table 7.3: Ongoing MA09-hRPE (Ocata Therapeutics) Clinical Trials in SMD, 2015
  • Table 7.4: Ongoing MA09-hRPE (Ocata Therapeutics) Clinical Trials in AMD, 2015
  • Table 8.1: Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2020
  • Table 8.2: Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2027
  • Table 8.3: Osteocel Plus Forecast (NuVasive): Revenues ($m), AGR (%), CAGR (%), 2014-2020
  • Table 8.4: Osteocel Plus Forecast (NuVasive): Revenues ($m), AGR (%), CAGR (%), 2021-2027
  • Table 8.5: Trinity Evolution and Elite (Orthofix): Revenues ($m), AGR (%), CAGR (%), 2010-2014
  • Table 8.6: Trinity Evolution and Elite (Orthofix) Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2020
  • Table 8.7: Trinity Evolution and Elite (Orthofix) Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2027
  • Table 8.8: CARTISTEM Revenues: Revenue ($m), AGR (%), 2013-H1 2015
  • Table 8.9: CARTISTEM (MEDIPOST) Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2020
  • Table 8.10: CARTISTEM (MEDIPOST) Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2027
  • Table 8.11: Non-Oncologic Diseases which can be Treated with HSCT
  • Table 8.12: Processes and Mechanisms of Bone Repair
  • Table 8.13: Anterogen Clinical Trials, 2016
  • Table 8.14: PDA-002 (Celgene Corporation) Current Clinical Trials, 2016
  • Table 8.15: PNEUMOSTEM (MEDIPOST) Past and Present Clinical Trials, 2016
  • Table 8.16: Translational Biosciences Currently Open Clinical Trials, 2016
  • Table 8.17: S-Evans Biosciences Clinical Trials, 2016
  • Table 9.1: Stem Cell Non-Therapeutic Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2020
  • Table 9.2: Stem Cell Non-Therapeutic Applications Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2021-2027
  • Table 9.3: Select US Stem Cell Banks, 2016
  • Table 9.4: Select Non-US Stem Cell Banks, 2016
  • Table 9.5: Select Stem Cell Supply and Processing Companies, 2016
  • Table 9.6: Select Companies with Involvement in Stem Cell-Based Assays, 2016
  • Table 10.1: World 65+ Population Forecast: Population (m), CAGR (%), 2015-205

List of Figures

  • Figure 1.1: Global Stem Cell Technologies and Applications Market Segmentation Overview, 2017
  • Figure 2.1: Timeline of Stem Cell Research
  • Figure 3.1: NIH Embryonic Stem Cell Registry: Stem Cell Lines by Status, 2016
  • Figure 3.2: NIH Spending for stem cell research by year (in USD billions)
  • Figure 3.3: CIRM Funding by Disease Area, Percentage (%), 2015
  • Figure 4.1: Therapeutic Applications of Stem Cells vs Non-Therapeutic Applications: Market Shares (%), 2016
  • Figure 4.2: Therapeutic Applications of Stem Cells vs Non-Therapeutic Applications: Market Shares (%), 2027
  • Figure 4.3: Stem Cell Technologies and Applications Market by Region: Market Shares (%), 2016
  • Figure 4.4: Stem Cell Technologies and Applications Market by Segment: Market Shares (%), 2016
  • Figure 4.5: Stem Cell Technologies and Applications Market Forecast: Revenues ($m), 2016-2027
  • Figure 4.6: Stem Cell Technologies and Applications Market Forecast by Segment: Revenue ($m), 2016-2027
  • Figure 4.7: Stem Cell Technologies and Applications Market Forecast by Segment, 2016-2027
  • Figure 4.8: Stem Cell Technologies and Applications Market: Market Shares (%) by Segment, 2021
  • Figure 4.9: Stem Cell Technologies and Applications Market: Market Shares (%) by Segment, 2027
  • Figure 4.10: Stem Cell Technologies and Applications Market: Drivers and Restraints, 2016-2027
  • Figure 5.1: Stem Cell Cancer Therapeutics Market Forecast: Revenue ($m), 2016-2027
  • Figure 5.2: Estimated Proportions of Global HSCT Operations by Donor Type, 2016
  • Figure 5.3: European HSCT Operations by Donor Type, 2003-2012
  • Figure 5.4: European HSCT Operations: Number of Operations by Donor Type, 2003-2012
  • Figure 5.5: Estimated New Cases of Leukemia, Lymphoma and Myeloma in 2016
  • Figure 5.6: Estimated new cases of leukemia diagnosed in 2016
  • Figure 5.7: HSCT-Addressable Cancers: Estimated Combined Incidence in the US, Japan and Western Europe (Number of Cases), 2012-2024
  • Figure 5.8: Most Common Diseases Treated by Cord Blood from LifeCord: Percentage (%) 2016
  • Figure 5.9: MSC-100-IV / Temcell HS Forecast (Mesoblast / JCR Pharmaceuticals): Revenue ($m), 2016-2027
  • Figure 5.10: Stem Cell Cancer Therapeutics Market: Drivers and Restraints, 2016-2027
  • Figure 6.1: Stem Cell Cardiovascular Therapeutics Market Forecast: Revenue ($m), 2016-2027
  • Figure 6.2: Global Cardiovascular Disease Market by Drug Class: Market Shares (%), 2016
  • Figure 6.3: Projected Global Deaths from Ischaemic Heart Disease and Stroke (millions ), 2015 and 2030
  • Figure 6.4: Hearticellgram-AMI (Pharmicell) Sales Estimates: Revenue ($m), 2012-2016
  • Figure 6.5: Hearticellgram-AMI (Pharmicell) Forecast: Revenue ($m), 2016-2027
  • Figure 6.6: CardioRel (Reliance Life Sciences) Forecast: Revenue ($m), 2016-2027
  • Figure 6.7: Stem Cell Cardiovascular Therapeutics Market: Drivers and Restraints, 2016-2027
  • Figure 7.1: Stem Cell CNS Therapeutics Market Forecast: Revenue ($m), 2014-2026
  • Figure 7.2: Stem Cell CNS Therapeutics Market: Drivers and Restraints, 2016-2027
  • Figure 8.1: Stem Cell Therapeutics in Other Disease Areas Market Forecast: Revenues ($m), 2016-2027
  • Figure 8.2: Osteocel Plus (NuVasive) Forecast: Revenue ($m), 2016-2027
  • Figure 8.3: Trinity Evolution and Elite (Orthofix): Revenue ($m), 2010-2014
  • Figure 8.4: Trinity Evolution and Elite (Orthofix): Revenue ($m), 2016-2027
  • Figure 8.5: CARTISTEM (MEDIPOST) Forecast: Revenues ($m) 2016-2027
  • Figure 9.1: Stem Cell Non-Therapeutic Applications Market Forecast: Revenue ($m), 2016-2027
  • Figure 9.2: Stem Cell Non-Therapeutic Applications Market: Drivers and Restraints, 2016-2027
  • Figure 10.1: SWOT Analysis of the Stem Cell Technologies and Applications Market, 2016-2027
  • Figure 10.2: STEP Analysis of the Stem Cell Technologies and Applications Market 2016-2027
  • Figure 10.3: World 65+ Population Forecast: Population (m), 2015-2050
  • Figure 11.1: Stem Cell Technologies and Applications Market Forecast, split by Therapeutic vs Non-Therapeutic Applications: Revenue ($m), 2016-2027

Companies Listed

  • Aastrom Biosciences
  • Advanced Cell Technology
  • Alder Biopharmaceuticals
  • Alkems
  • AllCells
  • Allergan
  • AlloSource
  • American Academy of Neurology
  • American Academy of Pediatrics (AAP)
  • American Neurological Associates Annual Meeting
  • American Society of Blood and Marrow Transplantation.
  • Americas Committee for Treatment and Research in Multiple Sclerosis
  • Americord
  • Amgen
  • Angiocrine Bioscience
  • Anterogen
  • Arteriocyte
  • Associated Press
  • Asterias Biotherapeutics
  • Athersys
  • Auriga Ventures
  • Axiogenesis
  • Baxter Healthcare
  • BaYi Brain Hospital
  • BioCardia
  • BioE
  • BioEden
  • Biogenea-Cellgenea
  • Bioheart, Inc
  • Biologic Therapies
  • BioMet Orthopedics
  • BioTime
  • BioTime Asia
  • Blackstone Medical
  • Bluebird Bio
  • BMJ (The British Medical Journal)
  • Boston Children's Hospital
  • BrainStorm Cell Therapeutics
  • Caladrius Biosciences
  • California Institute for Regenerative Medicine (CIRM)
  • Calimmune
  • Capricor
  • Cardio3
  • Caribou
  • Carolinas Cord Blood Bank (CCBB)
  • Casey Eye Institute
  • Cedars-Sinai Heart Institute
  • Cell Cure Neurosciences
  • Cell Therapy Catapult
  • CellCentric
  • Cellectis
  • Cellerant Therapeutics
  • Cellerix
  • CELLTREE
  • Cellular Biomedicine Group (CBMG)
  • Cellular Dynamics International
  • Center for International Blood and Marrow Transplant Research (CIBMTR)
  • Centers for Medicare & Medicaid Services
  • Cephalon
  • Cesca Therapeutics
  • Ceylad
  • Cha General Hospital
  • China Cord Blood Corporation
  • China Food and Drug Administration (CFDA)
  • Chinese Academy of Sciences
  • Chinese Ministry of Health
  • Chinese Ministry of Science and Technology
  • CJ CheilJedang
  • Clal Biotechnologies Industries
  • Cleveland Biolabs
  • Clinicaltrials.gov
  • ClinImmune Labs
  • Cochrane
  • Cognate BioServices
  • Committee for Medicinal Products for Human Use (CHMP)
  • Consortium of Multiple Sclerosis Centers
  • Cook General BioTechnology
  • Cord Blood America
  • Cord Blood Registry Systems
  • Cordlife Group
  • CRISPR Therapeutics
  • Cryo-Cell International
  • CryoCord
  • Cryonix CJSC
  • Cryo-Save
  • CXR Biosciences
  • Cytori Therapeutics
  • Data Safety Monitoring Board (DSMB)
  • Denali Ventures
  • Dendreon
  • Dong-A Pharmaceuticals Co
  • Drugs and Cell Therapies in Haematology (Journal)
  • Duke University School of Medicine
  • Elbit Imaging
  • Elbit Medical Technologies
  • Eli Lilly
  • Elsevier
  • EMA
  • EMA Committee for Orphan Medicinal Products
  • EpiStem
  • ESI Bio
  • European Court of Human Rights
  • European Court of Justice
  • European Group for Blood and Marrow Transplantation (EBMT)
  • European Haematology Association
  • EuroStemCell
  • Fate Therapeutics
  • FDS Pharma
  • Federal D.C. Court of Appeals
  • Fondazione Centro San Raffaele
  • Fondazione Telethon
  • Forbion Capital Partners
  • Forticell Bioscience
  • Gamida Cell
  • Gemabank
  • Gene Therapy Advisory Committee
  • Genetico
  • Genetrix Group
  • Geron
  • Gilead
  • GlobalStem
  • Globocan
  • GSK
  • Harvard Apparatus Regenerative Technology
  • Harvard Business School
  • Harvard Stem Cell Institute
  • Harvard University
  • Howard Hughes Medical Institute
  • Human Fertilisation and Embryology Authority (HFEA)
  • Human Stem Cells Institute
  • Human Tissue Authority
  • ImmunoCellular Therapeutics
  • Immunovative Therapies
  • Indian Department of Biotechnology
  • Insception Biosciences
  • Intellia Therapeutics
  • IntelliCell Biosciences
  • International Society for Stem Cell Research (ISSCR)
  • International Stem Cell Corporation (ISCO)
  • International Stemcell Services
  • IPS Academia Japan
  • Isar Medical Centre
  • Israel Healthcare Venture
  • Israel Stem Cell Society
  • Japan Institute of Biomedical Research.
  • Japan's Ministry of Economy, Trade and Industry (METI)
  • Japanese Health Ministry
Back to Top